Loading
A phase 3 trial of Florastamin[18F] Injection in prostate cancer, run by HTA Co., Ltd., now recruiting.
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT06754085 by HTA Co., Ltd., with 131 participants planned, started 2024-12-19 and due to reach its primary completion in 2026-01-01. Interventions recorded: Florastamin[18F] Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/